Wall Street Zen Downgrades Allovir (NASDAQ:KLRS) to Sell

Allovir (NASDAQ:KLRS) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Monday.

Allovir Price Performance

NASDAQ:KLRS opened at $3.08 on Monday. Allovir has a fifty-two week low of $2.64 and a fifty-two week high of $24.15.

Allovir Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.